コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ercent and 83 percent for the measurement of serum testosterone.
2 ncy and fertility, hypogonadism, and reduced serum testosterone.
3 vity risk for each 1-ng/mL increase in total serum testosterone.
4 one to achieve physiologic concentrations of serum testosterone.
5 Prednisone was the major predictor of serum testosterone.
6 ing VEGF164 expression with little change of serum testosterone.
7 ation, with elevated serum estradiol and low serum testosterone.
8 ion between risk of cognitive impairment and serum testosterone.
11 n over Black American men, we determined the serum testosterone and associated lipid levels in 250 Bl
12 here were weak negative correlations between serum testosterone and bone density (-0.20 < r < -0.28;
13 se effect of CsA and no relationship between serum testosterone and bone density change were detected
17 when given in dosages of 300 mg/d, increases serum testosterone and estradiol concentrations in some
20 t of a single 100-mg androstenedione dose on serum testosterone and estrogen concentrations was deter
22 Blood samples were obtained to measure total serum testosterone and perform the FibroSURE-ActiTest.
25 or radiologic progression on ADT, suppressed serum testosterone, and no limits for the number of prev
26 onstrated the greatest percentage decline in serum testosterone, androsterone, and dehydroepiandroste
31 d Leydig cell hypoplasia and lower levels of serum testosterone, but it is not clear whether this is
32 ual dysfunction has not been associated with serum testosterone, but this may be confounded by limita
33 sive disease, while racial disparity between serum testosterone, cholesterol and cancer mortality has
34 ed a mean increase of 271 ng/dl in the nadir serum testosterone concentration (to the middle of the n
35 zman rats were used to observe the course of serum testosterone concentration following orchiectomy (
36 gned 790 men 65 years of age or older with a serum testosterone concentration of less than 275 ng per
37 ular volumes (18+/-5 vs. 3+/-2 ml, P<0.001), serum testosterone concentrations (78+/-34 vs. 49+/-20 n
38 oxically, rapid cycling between high and low serum testosterone concentrations (bipolar androgen ther
39 men with prostate cancer, PC-SPES decreased serum testosterone concentrations (P<0.05), and in eight
43 ndicate that, within the normal range, lower serum testosterone concentrations are not associated wit
44 ion despite androgen-deprivation therapy and serum testosterone concentrations at castrate levels (<=
47 f the first studies to examine correlates of serum testosterone concentrations in anticipation of the
48 f testosterone therapy is usually to achieve serum testosterone concentrations in the male reference
49 rine differentiation or small-cell features, serum testosterone concentrations of 1.73 nmol/L or less
50 stenedione supplementation does not increase serum testosterone concentrations or enhance skeletal mu
51 that DHEA supplementation does not increase serum testosterone concentrations or increase strength i
52 hanges in the area under the curve (AUC) for serum testosterone concentrations were -2% (7%), -4% (4%
53 opathic infertility, sexual dysfunction, low serum testosterone concentrations, and apulsatile secret
57 efined as rapid cycling between high and low serum testosterone, disrupts this adaptive regulation in
58 KISS) neuron SEs, pulsatile LH secretion, or serum testosterone, estradiol, and progesterone concentr
63 s (age at diagnosis, 2 days to 11 years) and serum testosterone in 54 of them either after the admini
66 ), while no different change was observed in serum testosterone in male subjects and the sex hormone-
69 lyses and measurements of testicular volume, serum testosterone, inhibin B, and gonadotropins in thes
71 ty and prostate cancer include the impact on serum testosterone, leptin, insulin-like growth factor I
72 s, 788 men who were 65 years or older with a serum testosterone level less than 275 ng/mL and impaire
73 er, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter
75 liter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per millilit
76 underwent coronary angiography and had a low serum testosterone level, the use of testosterone therap
78 hypotheses by examining associations between serum testosterone levels (an indirect index of activati
79 g of supraphysiologic androgen (SPA) and low serum testosterone levels - is an alternative concept, b
80 ative analysis revealed that despite similar serum testosterone levels among the groups, the volume o
82 dual variability, and the connection between serum testosterone levels and clinical psychiatric signs
83 eover, high-fat feeding induces elevation of serum testosterone levels and enlargement of seminal ves
85 re observed in the Six5+/- and Six5-/- mice, serum testosterone levels and intra-testicular inhibin a
86 rength and function correlated directly with serum testosterone levels and inversely with CAG repeat
87 regarding the effects of varicocelectomy on serum testosterone levels are limited and conflicting.
91 ecovery in parallel with peaks and nadirs in serum testosterone levels during intermittent testostero
92 er age-related or obesity-related decline in serum testosterone levels has increased exponentially ev
93 tween alleles of this polymorphism and total serum testosterone levels in both affected and unaffecte
94 tor inhibition in vivo significantly reduced serum testosterone levels in male mice, demonstrating th
95 [22.2 nmol/L]) with no significant change in serum testosterone levels in matched, placebo-treated me
96 n the basis of prior hormone exposure and by serum testosterone levels into androgen-dependent and an
97 aged 65 years or older with an average of 2 serum testosterone levels lower than 275 ng/dL (82 men a
98 44 men, aged 44 to 78 years, with screening serum testosterone levels lower than 300 ng/dL (<10.4 nm
101 ason, we found no association between female serum testosterone levels or AGD on the number of male m
103 Testosterone replacement therapy increased serum testosterone levels to the mid-normal range (media
107 d a lower maximum growth velocity, and their serum testosterone levels were significantly lower compa
108 female birds and mammals suggests that high serum testosterone levels, and the exposure to high test
109 maturation (bone age), pubertal progression, serum testosterone levels, height velocity, and stature
110 incomplete germ cell development and lowered serum testosterone levels, which resulted in azoospermia
115 f abiraterone, a CYP17 inhibitor that lowers serum testosterone (< 1 ng/dL) and improves survival in
116 s were highly and negatively associated with serum testosterone (males: r = -0.746 and females: r = -
117 inhibiting substance was more sensitive than serum testosterone measurement for the identification of
118 roduction experienced a profound decrease in serum testosterone (median 540 to 36 ng/dl; p < 0.0001).
121 ncer survivors with low-normal morning total serum testosterone, replacement with testosterone is ass
122 ively associated with cotton wool spots, and serum testosterone response during flight was associated
123 at (1) alcohol induces profound reduction of serum testosterone, resulting in loss of androgen-regula
125 o loci, SHBG at 17p13 and FAM9B at Xp22, for serum testosterone (T) levels; however, these explain on
130 90 (mean age, 49.6 [SD, 11.5] years) had new serum testosterone tests and 283317 (mean age, 51.8 [SD,